Back to search results

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Solid Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • CBCC Global Research Site 001, Scottsdale, Arizona, United States

  • CBCC Global Research Site 005, Bakersfield, California, United States

  • CBCC Global Research Site 007, El Segundo, California, United States

  • CBCC Global Research Site 008, Santa Monica, California, United States

  • CBCC Global Research Site 003, Stanford, California, United States

  • CBCC Global Research Site 002, Portland, Oregon, United States

  • CBCC Global Research Site 006, Dallas, Texas, United States

Study leads

  • Richard Fahrner, PhD

    Study Director

    Alyssum Therapeutics

View source on ClinicalTrials.gov(opens in a new tab)